Business
IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
- IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020 - PARG and
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"- IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020\n - PARG and Pol Theta programs targeting Development Candidate in 2021\n - Targeting IDE196 / binimetinib combination dose selection and expansion in Q1 2021\n - Anticipate interim data in 2021 for each of IDE196/binimetinib combination arm and IDE196 monotherapy arm of Phase 1/2 GNAQ/11 basket trial\n\n\nSOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2020.\n\n \n \n \n \n \n \n\n \n\"We are advancing a broad pipeline of potential first-in-class synthetic lethality programs and executing on our IDE196 clinical strategy, including MEK and cMET combinations in MUM, and monotherapy development in skin melanoma and additional non-MUM GNAQ/11 solid tumors. Our synthetic lethality pipeline includes three programs recently partnered with GSK targeting MAT2A, Pol Theta and Werner Helicase, as well as three wholly-owned or controlled programs targeting PARG, DNA Damage Target 1 (DDT1) and DNA Damage Target 2 (DDT2). We are continuing to invest in our synthetic lethality platform, including through our strategic partnerships with the Broad Institute and UCSD, and enhancing our internal research capabilities to extend our leadership in synthetic lethality,\" said Yujiro S. Hata, Chief Executive Officer and President of IDEAYA Biosciences. \nProgram Updates\nKey highlights for IDEAYA's pipeline programs include: \nIDE397 (MAT2A)\nIDEAYA is developing IDE397, a potent and selective small molecule inhibitor targeting MAT2A, for solid tumors with MTAP deletions, a patient population estimated to represent approximately 15% of solid tumors. IDEAYA continues to lead research and development on the MAT2A program through early clinical development. Subject to exercise of its option, GSK will lead later stage global clinical development. Highlights:\nEvaluating efficacy of monotherapy IDE397 in over forty patient-derived xenograft (PDX) models with homozygous MTAP deletions in solid tumors; Completed in-life phase of good laboratory practi...